Floatz logo

FENTANYL

Systemic Mastocytosis

City of Hope Medical CenterSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Systemic Mastocytosis cohort.

Asset / SponsorPhaseRating
Imatinib
Novartis Pharmaceuticals
Phase 2B
Brentuximab Vedotin
Jason Robert Gotlib
Phase 2B
Denileukin Diftitox
M.D. Anderson Cancer Center
Phase 2CCC
HUMANIZED, DUAL-AFFINITY RE-TARGETING, OR (DART), MOLECULE THAT RECOGNIZES BOTH CD123 AND CD3
City of Hope Medical Center
Phase 2CCC
Ibrutinib
Jason Robert Gotlib
Phase 2CCC

View all 14 →

Same molecule, other indications

FENTANYL is also rated in:

Low Back PainDormant
BBB
Indicative ·
75 / 100
View asset →
PainDormant
BBB
Indicative ·
74 / 100
View asset →
chronic pain syndromeDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →